全文获取类型
收费全文 | 378篇 |
免费 | 17篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 20篇 |
妇产科学 | 2篇 |
基础医学 | 25篇 |
口腔科学 | 1篇 |
临床医学 | 35篇 |
内科学 | 125篇 |
皮肤病学 | 2篇 |
神经病学 | 17篇 |
特种医学 | 1篇 |
外科学 | 18篇 |
综合类 | 36篇 |
预防医学 | 17篇 |
眼科学 | 6篇 |
药学 | 68篇 |
中国医学 | 11篇 |
肿瘤学 | 18篇 |
出版年
2023年 | 19篇 |
2022年 | 18篇 |
2021年 | 17篇 |
2020年 | 19篇 |
2019年 | 11篇 |
2018年 | 19篇 |
2017年 | 18篇 |
2016年 | 11篇 |
2015年 | 7篇 |
2014年 | 18篇 |
2013年 | 26篇 |
2012年 | 26篇 |
2011年 | 16篇 |
2010年 | 16篇 |
2009年 | 12篇 |
2008年 | 13篇 |
2007年 | 9篇 |
2006年 | 10篇 |
2005年 | 9篇 |
2004年 | 5篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 7篇 |
1997年 | 7篇 |
1996年 | 4篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1990年 | 1篇 |
1989年 | 5篇 |
1988年 | 8篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 4篇 |
1978年 | 1篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有403条查询结果,搜索用时 843 毫秒
81.
Hyosook Hwang Hyeon-Soo Kim JeongIl Kwon Phil-Sun Oh Ho Sung Park Seok Tae Lim Myung-Hee Sohn Hwan-Jeong Jeong 《Journal of vascular and interventional radiology : JVIR》2018,29(4):575-583
Purpose
To investigate potential of chitosan hydrogel microparticles (CHI) for treatment of VX2 carcinoma.Materials and Methods
Two weeks after liver VX2 implantation, contrast-enhanced computerized tomographic scanning was conducted. Rabbits (n = 2) with successful tumor growth were treated with different sizes of 99mTc-labeled CHI (60–80 μm and 100–120 μm) via intra-arterial hepatic catheterization. Liver distribution of 99mTc-labeled CHI was determined by means of autoradiography, a radiation-based photographic technique. In the next part of this study, therapeutic effectiveness was examined with the use of CHI with the size range of 60–80 μm (n = 11). Tumor growth response and levels of blood liver enzymes were studied at baseline and 1 and 2 weeks after CHI treatment.Results
Successful tumor growth was confirmed in all rabbits (24/24). Intrahepatic CHI with the size range of 60–80 μm resulted in liver localization in more close proximity to tumor nodule versus 100–120 μm. Baseline tumor volume was 1,909 ± 575 mm3 in animals receiving CHI versus 1,831 ± 249 mm3 in control animals (P = .342). In control animals, tumor volume markedly increased by 1,544 ± 512% at 2 weeks after sham operation versus baseline. In animals receiving CHI, tumor volume remained relatively unchanged (54 ± 6% increase; P = .007 vs control). Levels of blood aspartate transaminase (AST) and alanine transaminase (ALT) in animals receiving CHI increased 1 week after treatment (P = .032 vs control for AST; P = .000 vs control for ALT), but returned to control levels at 2 weeks.Conclusions
CHI embolization suppressed tumor growth without appreciable damages in liver function. 相似文献82.
目的 探讨血清腺苷脱氨酶(ADA)在急性髓系白血病(AML)的变化规律及其意义.方法 收集山东省立医院2012年1月至2013年12月75例治疗前急性髓系白血病患者(其中63例AML患者进行自身治疗前后比较)和86例健康对照者外周血血清.采用PNP-XTO-POD偶联连续监测法测定血清腺苷脱氨酶(ADA)水平,采用速率法测定谷草转氨酶(AST)、谷丙转氨酶(ALT)和谷氨酰转肽酶(GGT)水平.检测健康对照组与AML组血清ADA水平,比较AML治疗前后ADA水平变化,采用受试者工作特征曲线(ROC曲线)确定ADA最佳截点,并将AML治疗前患者分为低ADA组(ADA<13.50 U/L)和高ADA组(ADA≥13.50 U/L),分析两组间年龄、性别、AST、ALT和GGT差异.结果 AML组患者ADA水平[15.30(9.50,31.30)U/L]显著高于健康对照组[8.45(7.05,11.35)U/L],差异有统计学意义(P<0.001);AML组治疗后ADA水平[10.70(8.10,14.90)U/L]显著低于AML治疗前[14.70(9.60,26.70)U/L],差异有统计学意义(P<0.001);采用ROC曲线,将AML治疗前患者分为高ADA组(ADA≥13.50 U/L)和低ADA组(ADA<13.50 U/L),其中高ADA组中AST、ALT及GGT水平显著高于低ADA组(AST Z=-3.102,P=0.002;ALT Z=-2.046,P=0.041;GGT Z=-2.794,P=0.005).结论 ADA检测可以作为AML患者的一项常规辅助检查,对AML的疾病诊断及评估病情的发展具有一定的价值. 相似文献
83.
《Clinical nutrition (Edinburgh, Scotland)》2020,39(3):727-736
- Download : Download high-res image (71KB)
- Download : Download full-size image
84.
85.
Huiping Li Xuena Wang Mingxu Ye Shunming Zhang Qing Zhang Ge Meng Li Liu Hongmei Wu Yeqing Gu Yawen Wang Tingjing Zhang Shaomei Sun Xing Wang Ming Zhou Qiyu Jia Kun Song Yaogang Wang Kaijun Niu 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(6):1691-1701
Background and aimsResults of in vitro and in vivo studies showed that green leafy vegetables (GLV) could attenuate liver steatosis. However, little is known regarding the association between GLV intake and nonalcoholic fatty liver disease (NAFLD) in human. We examined the association of GLV intake with NAFLD in a large-scale adult population.Methods and resultsThis cross-sectional study investigated 26,891 adults in China who participated in health examinations from 2013 to 2017. Newly diagnosed NAFLD was detected by liver ultrasonography. Dietary intake was assessed by using a validated and standardized food frequency questionnaire. Multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) across categories of GLV intake. After adjustment for sociodemographic characteristics, lifestyle factors, and other dietary intakes, the OR (95% CI) for comparing the highest vs. lowest GLV intake categories (≥7 times/week vs. almost never) was 0.72 (0.59, 0.90) (P < 0.0001). In addition, a linear inverse association was demonstrated between GLV intake and NAFLD in women (P for trend = 0.04), but ORs for any intake category did not reach significance. Stratified analyses suggested a potential effect modification by obesity status; the ORs (95% CIs) for comparing the highest vs. lowest GLV intake categories was 0.72 (0.54, 0.97) in normal/overweight individuals and 1.04 (0.65, 1.65) in obese individuals (P-interaction < 0.0001).ConclusionThis large population-based study shows that high GLV intake is inversely associated with NAFLD, particularly in women and non-obese participants. 相似文献
86.
《Gastroenterologia y hepatologia》2022,45(1):47-58
IntroductionCorrectly identifying patients with biliary atresia (BA), while avoiding invasive diagnostic methods is challenging. The purpose of this study was to determine the value of serum immune indicators for distinguishing BA from other causes of cholestasis in infants.Patients and methodsThe data of infants with a surgical/histological diagnosis of BA and those with other causes of cholestatic jaundice were retrospectively analyzed. Patients were divided into a BA group and a cholestasis control (CC) group. Biochemical parameters, major lymphocyte subsets, immunoglobin and C3 and C4 complement levels were compared between the groups.ResultsA total of 129 infants with BA and 63 with other causes of cholestasis (CC control group) with a median age of 2.2 months were included in the analysis. The levels of CD3+ T cells, CD3+CD4+ T cells, and premature T cells and the levels of C3 and C4 were all significantly higher in the BA group compared to the CC group (all P < 0.05). Pair-wise correlation analyses indicated that C3 and C4 had a significant positive correlation with γ-GT in the BA group, but not in the CC group. Five indices were found to be significantly associated with BA: stool color, globulin, γ-GT, C3 and C4. A model incorporating stool color, gamma-glutamyl transpeptidase level, and C3 level exhibited an area under the ROC curve (AUC) of 0.93, and a sensitivity of 93% and specificity of 83% for the diagnosis of BA.ConclusionsModels incorporating serum C3 levels may be useful for accurately diagnosing BA in infants. 相似文献
87.
Alessio Gerussi Davide Paolo Bernasconi Sarah Elisabeth O'Donnell Willem J. Lammers Henk Van Buuren Gideon Hirschfield Harry Janssen Christophe Corpechot Anna Reig Albert Pares Pier Maria Battezzati Massimo Giovanni Zuin Nora Cazzagon Annarosa Floreani Frederik Nevens Nikolaos Gatselis George Dalekos Marlyn J. Mayo Marco Carbone 《Clinical gastroenterology and hepatology》2021,19(8):1688-1697.e14
88.
Rosalinda Posadas-Sánchez Javier Ángeles-Martínez Nonanzit Pérez-Hernández José Manuel Rodríguez-Pérez Fabiola López-Bautista Teresa Villarreal-Molina José Manuel Fragoso Carlos Posadas-Romero Gilberto Vargas-Alarcón 《Experimental and molecular pathology》2017,102(1):1-6
The receptor-interacting protein 2 (Rip2) is a serine/threonine kinase involved in multiple nuclear factor-κB (NFκB) activation pathways and is a key regulator of cellular lipid metabolism and cardiovascular disease. The aim of the present study was to evaluate the role of RIP2 gene polymorphisms as susceptibility markers for subclinical atherosclerosis (SA). Using an informatics analysis, four RIP2 gene polymorphisms with predicted functional effects (rs2293808, rs43133, rs431264, and rs16900627) were selected. The polymorphisms were genotyped in 405 individuals with SA (calcium score > 0 assessed by computed tomography) and 1099 controls (calcium score = 0). Clinical, anthropometric, tomographic and biochemical traits were measured. The association between the RIP2 polymorphisms and SA was evaluated using logistic regression analyses. Pair wise linkage disequilibrium (LD, D′) estimations between polymorphisms and haplotype reconstruction were performed with Haploview version 4:1. Under different models adjusted by age, gender, body mass index, hypertension, diabetes mellitus, smoking habit, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride levels, rs43133 (OR = 1.43, 95% CI: 1.05–1.94, P = 0.022), and rs16900627 (OR = 1.59, 95% CI: 1.00–2.54, Pdom = 0.048 and OR = 1.60, 95% CI: 1.05–2.54, Padd = 0.028) were associated with increased risk of developing SA. Moreover, rs2293808, and rs431264 were associated with clinical or metabolic parameters in SA individuals and in healthy controls. The four polymorphisms were in high linkage disequilibrium and the GAAG haplotype was associated with increased risk of developing SA (OR = 1.47, P = 0.027). This study shows for the first time, that RIP2 polymorphisms are associated with increased risk of SA and with some clinical and metabolic parameters. 相似文献
89.
Dee Pei Te-Lin Hsia Ting-Ting Chao Jiunn-Diann Lin Chun-Hsien Hsu Chung-Ze Wu Chang-Hsun Hsieh Yao-Jen Liang Yen-Lin Chen 《Saudi Journal Of Gastroenterology》2015,21(3):158-164
Background/Aims:
Nonalchoholic fatty liver disease (NAFLD) has been reported as a hepatic manifestation of metabolic syndrome (MetS); it is common and accounts for 80% of the cases with abnormal liver function tests (LFTs). In addition, several studies have proved that there is a correlation between abnormal LFTs and MetS. Therefore, LFTs may represent the abnormal metabolic status of livers in the patients with MetS. To identify the early state of metabolic dysfunction, we investigate the value of LFTs for the future MetS development in the relatively healthy (non-NAFLD) elderly.Patients and Methods:
A total of 16,912 subjects met the criteria for analysis. In the first stage of this study, subjects were enrolled in the cross-sectional study in order to find out the optimal cutoff value in different LFTs with higher chances to have MetS. In the second stage of the present study, subjects with MetS at baseline were excluded from the same study group, and a median 5.6-year longitudinal study was conducted on the rest of the group.Results:
Among all LFTs, only aspartate aminotransferase in both genders and the α-fetal protein in women failed to show the significance in distinguishing subjects with MetS by the receiver operating characteristic curve. In the Kaplan–Meier plot, only γ-glutamyl transpeptidase (γ-GT) in men and the alanine aminotransferase (ALT) in women could be used to successfully separate subjects with higher risk of developing the MetS from those with lower risk. Finally, in the multivariant Cox regression model, similar results were identified. Still, the hazard ratio (HR) to have future MetS, γ-GT in men, and ALT in women showed significance (HR = 1.511 in men and 1.504 in women).Conclusion:
Among all the different LFTs, γ-GT (>16 U/L) in male and ALT (>21 U/L) in female were the best predictors for the development of MetS in healthy elderly. These two liver markers could be an ancillary test in predicting future MetS development/diagnosis. Elevation of the LFTs without underlying liver diseases should be treated as a warning sign of the possible MetS development in the elderly. 相似文献90.
Introduction and objectivesEvaluation of liver fibrosis is important for treatment decisions, complications and to predict prognosis in patients with chronic hepatitis B (CHB). Our aim was to develop a new non-invasive fibrosis scoring method and prove its accuracy in the differentiation of no/low grade and advanced fibrosis in patients with CHB.Patients and methodsOur study included 273 chronic hepatitis B patients who underwent liver biopsy from February, 2007 to February, 2019 with medical records retrospectively reviewed. Preparations of these patients were divided into two groups as ≤ 3 no-low grade fibrosis (n=236) and ≥ 4 advanced fibrosis (n=37) according to histological ISHAK fibrosis scoring system.ResultsThe newly developed AGAP score and other non-invasive fibrosis scores; Fibrosis-4 index, Aspartate aminotransferase to platelets ratio, Gamma glutamyl transpeptidase to platelet ratio, Goteborg University Cirrhosis Index, King's score, Albumin-bilirubin index, Fibrosis cirrhosis index, Fibrosis index, Fibrosis quotient, Lok score and mean and/or median values of Fibroindex were significantly higher in the advanced fibrosis group compared to the no/low grade fibrosis group (p<0.001). However, there was no significant difference in AAR score among the groups (p=0.265). With cut-off value of 4.038, AUROC value of 0.803, sensitivity of 75.7%, specificity of 73.7% and accuracy of 0.740, AGAP score showed the best performance in advanced fibrosis differentiation compared to 12 other non-invasive fibrosis scoring methods.ConclusionsThe newly developed AGAP score showed better performance in patients with CHB compared to 12 other non-invasive fibrosis scores in differentiation of no/low grade fibrosis and advanced fibrosis. 相似文献